Heather D. Brooks

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

Heather D. Brooks, Bonnie S. Glisson, B. Nebiyou Bekele et al. · Cancer · 2010 · 106 citations · Full text

Ublituximab ( <scp>TG</scp> ‐1101), a novel glycoengineered anti‐ <scp>CD</scp> 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan et al. · British Journal of Haematology · 2016 · 62 citations · Full text

Phase IIIb randomized study of lenalidomide plus rituximab (R²) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).

David Andorsky, Abdulraheem Yacoub, Jason M. Melear et al. · Journal of Clinical Oncology · 2017 · 21 citations

Cancer Management, Immunology, Initial Diagnosis +22

Isolated Polyarticular Septic Arthritis: An Atypical Presentation of Meningococcal Infection

Michael A. McCulloch, Heather D. Brooks, Kambiz Kalantarinia · The American Journal of the Medical Sciences · 2008 · 19 citations

Rheumatology, Polyarticular Septic Arthritis, Clinical Infection +3

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan et al. · Blood · 2014 · 15 citations